| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
miR-96 (microRNA-96) Drosha site.
|
|---|---|
| ln Vitro |
At micromolar concentrations, MIR96-IN-1 (compound 1) specifically suppresses the generation of mature miR-96 and induces the death of breast cancer cells [1]. Compound 3, or MIR96-IN-1, binds to the UU loop of miR-96 and prevents its synthesis [2].
MIR96-IN-1 selectively inhibits production of mature miR-96 and triggers apoptosis in breast cancer cells at micromolar concentrations. It inhibits Drosha cleavage of pri-miR-96, as evidenced by an increase in pri-miR-96 levels and a reduction in pre- and mature miR-96 levels in treated cells. MIR96-IN-1 efficiently and selectively silences production of miR-96 at 40 µM while not affecting miR-182 or miR-183. It reduces miR-96 expression by 90% at 40 µM. The compound upregulates FOXO1, a protein target of miR-96, and induces apoptosis. |
| ln Vivo |
In vivo efficacy data for MIR96-IN-1 is limited. The compound has been shown to inhibit miR-96 biogenesis in breast cancer cells and trigger apoptosis in vitro. As a microRNA inhibitor targeting an oncogenic noncoding RNA, it has potential applications in cancer therapy. Further in vivo studies in tumor xenograft models would be needed to assess its therapeutic potential. The compound is primarily used as a research tool for studying microRNA biology.
|
| Enzyme Assay |
The in vitro binding assay measures the affinity of MIR96-IN-1 for its RNA targets using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). Recombinant RNA corresponding to the Drosha site in the miR-96 hairpin precursor is immobilized on a sensor chip. Varying concentrations of MIR96-IN-1 (typically 0.1 to 100 µM) are injected over the chip, and binding is measured in real-time. The Kd values are calculated from the binding curves. Selectivity is assessed by profiling against other microRNA hairpin precursors.
|
| Cell Assay |
In vitro cellular assays are performed using breast cancer cell lines (e.g., MCF-7 or MDA-MB-231). Cells are treated with MIR96-IN-1 at concentrations ranging from 1 to 100 µM for 24-72 hours. miR-96 levels (pre-miR-96 and mature miR-96) are measured by quantitative RT-PCR. pri-miR-96 levels are measured to assess Drosha cleavage inhibition. Apoptosis is assessed by Annexin V/PI staining and flow cytometry, or by measuring caspase-3/7 activity. FOXO1 protein levels are measured by Western blot. Selectivity for miR-96 over miR-182 and miR-183 is confirmed by qRT-PCR.
|
| Animal Protocol |
In vivo animal model data for MIR96-IN-1 is not extensively reported in the literature. As a research tool for studying microRNA biology, the compound would typically be evaluated in mouse xenograft models using breast cancer cell lines. Standard efficacy studies would involve tumor growth inhibition as the primary endpoint. Pharmacokinetic studies would assess oral bioavailability, plasma half-life, and tissue distribution. The compound is primarily used as a molecular probe for in vitro studies.
|
| ADME/Pharmacokinetics |
MIR96-IN-1 has a molecular weight of 588.79 g/mol and molecular formula C33H48N8O2. It is soluble in DMSO (100 mg/mL) and should be stored as a powder at -20°C. The compound contains an azide group, making it a click chemistry reagent that can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC). In vivo formulation: 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline (≥ 2.5 mg/mL).
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available for MIR96-IN-1. As a research compound, it is not intended for human use and has not undergone formal toxicological evaluation. Standard preclinical safety assessments for microRNA inhibitors would typically include selectivity profiling against other microRNAs to assess off-target effects, hERG channel inhibition for cardiac safety, and CYP450 enzyme inhibition for drug-drug interaction potential. The compound is supplied as a solid and should be stored desiccated at -20°C.
|
| References | |
| Additional Infomation |
MIR96-IN-1 is a research-grade chemical probe for studying miR-96 biogenesis and function in cancer. It is not approved for clinical use. The compound contains an azide group and can be used in click chemistry applications. It selectively inhibits miR-96 biogenesis, upregulates FOXO1, and induces apoptosis in cancer cells. MIR96-IN-1 is supplied as a solid with high purity and should be stored desiccated at -20°C.
|
| Molecular Formula |
C33H48N8O2
|
|---|---|
| Molecular Weight |
588.8
|
| Exact Mass |
588.39
|
| CAS # |
1311982-88-3
|
| PubChem CID |
72699186
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
6.02
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
43
|
| Complexity |
910
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)(C)C1=CC(=CC(=C1OCCCC(=O)NCCCN=[N+]=[N-])C(C)(C)C)C2=NC3=C(N2)C=C(C=C3)N4CCN(CC4)C
|
| InChi Key |
LTPQCIXFOJELHJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C33H48N8O2/c1-32(2,3)25-20-23(31-37-27-12-11-24(22-28(27)38-31)41-17-15-40(7)16-18-41)21-26(33(4,5)6)30(25)43-19-8-10-29(42)35-13-9-14-36-39-34/h11-12,20-22H,8-10,13-19H2,1-7H3,(H,35,42)(H,37,38)
|
| Chemical Name |
N-(3-azidopropyl)-4-[2,6-ditert-butyl-4-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]phenoxy]butanamide
|
| Synonyms |
MIR96IN1; MIR96 IN 1; MIR96-IN-1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~169.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.25 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6984 mL | 8.4918 mL | 16.9837 mL | |
| 5 mM | 0.3397 mL | 1.6984 mL | 3.3967 mL | |
| 10 mM | 0.1698 mL | 0.8492 mL | 1.6984 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
